Tyrosine kinase inhibitors: new hope with new challenges
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: HO, Han Kiat (National University of Singapore, Department of Pharmacy, Singapore, Singapore)
The advent of molecular targeted therapy (most notably the tyrosine kinase inhibitors) for cancer treatment generates a distinct range of adverse effects that are different from conventional chemotherapy and are mechanistically unpredictable. In particularly, hepatotoxicity has been observed frequently, leading to black box warning labels being.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.